A novel therapy targeting the gut–liver axis for chronic hepatitis B: Ursodeoxycholic acid plus Bifidobacterium

Background & Aims: Targeting the gut–liver axis is a promising strategy for treating liver diseases. We aimed to assess the therapeutic efficacy of targeting the gut microbiota-bile acid (BA) axis using ursodeoxycholic acid (UDCA) combined with the probiotic Bifidobacterium to treat chronic hepa...

Descripció completa

Dades bibliogràfiques

Autors principals:	Zhen Xun, Xiaobao Yao, Caorui Lin, Xinyao Yang, Yanfang Zhang, Xin Yang, Yujue He, Renquan Jiang, Yanping Lan, Yuchen Ye, Detai Ye, Shanjian Chen, Ke Ma, Wennan Wu, Siyi Xu, Bin Yang, Can Liu, Jing Chen, Qi Zheng, Qishui Ou
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2025-08-01
Col·lecció:	JHEP Reports
Matèries:	Chronic hepatitis B Gut microbiota Bile acid Immune cells Treatment
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S258955592500134X
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!